The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Encorafenib and cetuximab with/without binimetinib therapies for patients with BRAF-mutated metastatic colorectal cancer with prognostic factors: The BEETS trial (JACCRO CC-18).
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Incyte; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Merck; MSD K.K
Research Funding - Chugai Pharma; Taiho Pharmaceutical
 
Eisuke Inoue
No Relationships to Disclose
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Guardant Health; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - MSD K.K; Seagen; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Tadamichi Denda
Honoraria - Ono Pharmaceutical
Speakers' Bureau - Daiichi-Sankyo; Ono Pharmaceutical
Research Funding - Amgen (Inst); Bristol Myers Squibb Foundation (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Chiaki Inagaki
Stock and Other Ownership Interests - Eisai
Speakers' Bureau - Daiichi Sankyo/UCB Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma; Epochal Precision Anti-Cancer Therapeutics; Ono Pharmaceutical
 
Tomomi Kashiwada
No Relationships to Disclose
 
Yosuke Horita
No Relationships to Disclose
 
Akinori Sugaya
No Relationships to Disclose
 
Yusuke Suwa
No Relationships to Disclose
 
Takashi Ohta
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; EA Pharma; Lilly Japan; Merck KGaA; Novartis; Taiho Pharmaceutical; Takeda
 
Hidekazu Kuramochi
No Relationships to Disclose
 
Kotoe Oshima
No Relationships to Disclose
 
Manabu Shiozawa
Speakers' Bureau - Johnson & Johnson; Kaken Pharmaceutical; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD K.K; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Akihito Tsuji
Speakers' Bureau - Bristol-Myers Squibb Corporation; Chugai Pharma; Lilly Japan; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Kei Muro
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International (Inst); PRA Health Sciences (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Wataru Ichikawa
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Guardant Health; Guardant Health; Kyowa Kirin; Lilly; Merck; MSD K.K; Nihonkayaku; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization